Anton Rx

We are incredibly grateful to our Presenting Sponsor Anton Rx for helping make the 2026 NDSS Gala & Auction a historic evening. Thank you for your commitment to our community and NDSS' mission. Because of your generous support, we raised over $1 million to create a world where individuals with Down syndrome thrive! 👏

🚀 Now Recruiting: Anton Academy | Clinical Pharmacy Internship (Nashville, TN)   Anton Academy is a hands-on summer internship for pharmacy students looking to break into managed care, market access, and the pharmaceutical industry.   This is not a traditional internship. You'll work on real projects that impact payer strategy, formulary decisions, and manufacturer planning — and present your findings directly to clients.   What you'll gain: • Direct exposure to managed care & market access across Anton Rx and Anton Health • Experience with clinical policy, drug pipeline research, and payer landscape strategy • Mentorship from Billy West, PharmD, MBA, FAMCP and our full clinical and trade team • A clear view of career paths beyond the traditional pharmacy roles   Dual-degree candidates (PharmD + MBA, MPH, MHA, or MS Health Informatics) are our priority — this is a program built for pharmacists who want to operate at the intersection of clinical and business.   📍 On-site at 301 Church Street, Nashville — in the heart of the nation's healthcare capital 💰 $25/hour | ~10 weeks (Summer 2026) 💼 P2+ PharmD students encouraged to apply   Interested or know someone who should be? Email Billy.West@antonhealth.com directly to learn more.   #PharmacyStudents #MarketAccess #ManagedCare #PharmaCareers #Internship #AntonAcademy #Nashville #FuturePharmacists

What an incredible evening at the 2026 NDSS Gala & Auction. We are so grateful to have played a small part in supporting the National Down Syndrome Society's mission. Over $1 million raised to create a world where individuals with Down syndrome thrive. Congratulations to the entire NDSS community on a truly historic night. 👏

On March 25, 2026, the FDA approved Avlayah (tividenofusp alfa-eknm) for the treatment of neurologic manifestations of Hunter syndrome (MPS II) in pediatric patients weighing at least 5 kg. It is the first new FDA-approved treatment for this condition in nearly 20 years and the first FDA-approved biologic designed to cross the blood-brain barrier. Link to the full article in the comments. #specialtypharmacy #marketaccess #fdaapproved

The denosumab biosimilar market has gone from quiet anticipation to a full sprint. In the past twelve months, the FDA has approved nine pairs of biosimilars referencing Prolia and Xgeva. Six have already launched commercially, with more expected throughout 2026. The latest, Teva's Ponlimsi, was approved on March 30. For a biologic franchise with combined U.S. sales exceeding $5 billion annually, this level of competition was expected. But the speed and volume of market entry raise questions that go well beyond the approval headlines. #specialtypharmacy #marketaccess #fdaapproved https://lnkd.in/ebqimmvb

Today marked the first day of a new pharmacy model at EmblemHealth. We officially launched pharmacy services with Prime Therapeutics, Judi Health/Capital Rx, Amazon Pharmacy, and Free Market Health. Today was an overwhelming success, and I couldn’t be more excited for the transparency, flexibility, and partnership with our new structure. The possibilities to deliver better care at lower costs are immense, and we are just getting started. Additional mentions to RazorMetrics, Levrx Technology Inc., and Anton Rx as additional parts of the overall solution. And to PayerAlly and PwC for their partnerships as well. The pharmacy team at EmblemHealth has worked incredibly hard to get to this point, and the vision and dedication has paid off. I am hopeful this model will become the standard for health plans and payers across the country. Happy New Year!

Celebrate with NDSS at A Night to Thrive, presented by our generous Legacy Sponsor, Anton Rx, with an acoustic performance by American rock band, Daughtry! 🎤 This evening will inspire a future where every person with Down syndrome can thrive, while raising critical funds to support the Down syndrome community. Get your tickets at ndss.org/events/gala and join us on March 12 in NYC!

Immunoglobulin (IG) has long been a specialized area within pharmacy, yet it continues to influence the broader market. As such, it’s important for pharmaceutical professionals to maintain at least a basic understanding of its role and impact. Today's article offers a deep dive into increasingly turbulent IG waters. In recent years, the landscape for immunoglobulin (IG) therapies – both intravenous (IVIG) and subcutaneous (SCIG) – has seen a wave of new entrants and formulations. While this offers important opportunities for improved treatment options, it also brings a suite of issues that pharmaceutical companies, specialty pharmacies, and clinicians need to navigate carefully. #specialtypharmacy #marketaccess https://lnkd.in/e3NcDHRT

Yeah, Yeah….  The message from the article below is preaching to the choir… but this hymn can’t be sung enough. The central message in this article is that pharmaceutical manufacturers are increasingly relying on “limited-distribution drug (LDD) networks” as a key channel strategy—and that providers seeking to participate must adopt a proactive posture early on to gain access. Specialty pharmacies and provider partners must anticipate and demonstrate the kinds of capabilities manufacturers are now demanding. #marketaccess  #specialtypharmacy https://lnkd.in/eKnaKz-X

Amid what some would call chaos in the halls of the FDA, HHS, etc., some light came shining through recently. The FDA announced a new collaborative approach to a procedural pathway called Rare Disease Evidence Principles (RDEP) targeted at ultra-rare genetic diseases. Under RDEP, drugs and biologics that meet defined criteria may engage earlier with FDA’s review teams to pre-negotiate what evidence can support a “substantial evidence of effectiveness” determination. FDA is signaling that it will more explicitly consider nontraditional evidence (e.g., single-arm trials, external control arms, natural history studies). #marketaccess #fdaapproved #specialtypharmacy https://lnkd.in/eRxA_Vw8